Expression and clinical significance of B-cell lymphoma 2 (BCL-2) in hyperleukocytic acute myeloid leukemia / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 851-856, 2013.
Article
in Chinese
| WPRIM
| ID: wpr-284021
ABSTRACT
This study was aimed to investigate the role of B-cell lymphoma 2 (BCL-2) in pathogenesis of hyperleukocytic acute myeloid leukemia (AML). The levels of intracellular BCL-2 in 48 AML patients were detected by flow cytometry (FCM). Serum levels of BCL-2 in 40 AML patients were measured by enzyme-linked immunosorbent assay (ELISA). The results showed that the serum levels of BCL-2 in hyperleukocytic AML and non-hyperleukocytic AML patients were significantly higher than that in normal controls (P < 0.05), but intracellular BCL-2 levels were not significantly different, as compared with normal controls (P > 0.05). There were no difference of intracellular and serum BCL-2 levels between hyperleukocytic and non-hyperleukocytic AML patients (P > 0.05). The serum and intracellular levels of BCL-2 between hyperleukocytic AML, non-hyperleukocytic AML patients and normal controls were not statistically correlated. It is concluded that leukemic cells in AML patients produce and secrete too much BCL-2, which may be involved in the pathogenesis of leukemia disease. However, the anti-apoptosis effect of BCL-2 has no significant impact on the pathogenesis of hyperleukocytic AML.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pathology
/
Blood
/
Leukemia, Myeloid, Acute
/
Case-Control Studies
/
Proto-Oncogene Proteins c-bcl-2
/
Flow Cytometry
Type of study:
Observational study
Limits:
Female
/
Humans
/
Male
Language:
Chinese
Journal:
Journal of Experimental Hematology
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS